|Bid||141.57 x 1200|
|Ask||144.10 x 800|
|Day's Range||142.92 - 144.29|
|52 Week Range||109.16 - 157.00|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||22.51|
|Earnings Date||Jan. 26, 2021|
|Forward Dividend & Yield||4.04 (2.81%)|
|Ex-Dividend Date||Nov. 23, 2020|
|1y Target Est||166.18|
Dr. David Lubarsky, UC Davis Health CEO, joins The Final Round to discuss the rise of new coronavirus cases worldwide, recent news coming out on the vaccine race, and how hospitals are preparing for a new surge.
On Tuesday, Pfizer confirmed that it enrolled 42,000 volunteers into its coronavirus vaccine trial. This comes as AstraZeneca says its vaccine demonstrated immune responses among adults and Russia begins production of its second coronavirus vaccine. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
For a while, the U.S. late-stage clinical trials of coronavirus vaccine candidates developed by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ) were in limbo. On Friday, AstraZeneca announced that the U.S. Food and Drug Administration authorized the resumption of the late-stage study for coronavirus vaccine candidate AZD1222. The same day, J&J announced that it also was preparing to resume the U.S. late-stage study of its experimental COVID-19 vaccine, JNJ-78436735.